About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. Distances, Work Furthermore, where permissible, we may charge for this service. This time around, we note that NextPoint Therapeutics hired Leena Gandhi as chief medical officer. State by any measure implementing the Prospectus Directive in that Relevant Member State, and the Viewing the materials you seek to access may not be lawful in certain NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. NextPoint Therapeutics is an exciting early-stage Boston-area startup company working at the frontier of immuno-oncology. Investing in a stronger future - for our shareholders, and As permitted by law, certain data elements may not be subject to access, modification, portability, restriction, and/or deletion. Financial He is currently CEO of portfolio company NextPoint Therapeutics and is also a board member of portfolio company iTeos Therapeutics (NASDAQ: ITOS). Reports, Bayer AG Nutrition KIR3DL3-HHLA2 is a human immunosuppressive pathway and a therapeutic target. Requests may be made only once a year and are free of charge. The securities mentioned herein have not been, and will not be, registered under the Securities Act Global R&D, Events & of for Read more about our economic, ecological and social challenges and opportunities. to proceed to electronic versions of these materials. Feel free to contact me at Joash.tan.kiat@gmail.com or +65 97857618! Our team of proven drug developers is working closely with our renowned scientific founders to launch a new world of precision immuno-oncology. In fiscal 2021, the Group employed around 100,000 people and had sales of 44.1 billion euros. Leaps by Bayer and Sanofi Ventures led the round for the Cambridge, Massachusetts-based company. In this article, I lay out what I see as three access to the materials is prohibited or restricted. Conduct, Product or from within the United States. These factors include those discussed in Bayers public reports which are available on the Bayer website at, . Management, Bayer For more information. Strong knowledge of pharmaceutical regulations e.g., GCP/ICH, GLP, GDPR, etc. Reporting to the Chief Medical Officer, the Vice President will build our Translational Medicine capability, responsible for managing research activities bridging from discovery to clinical development. Among these areas are oncology, immunology, rare diseases, vaccines, potential cures in other core areas of Sanofis business footprint, and digital health solutions. Patients, Beware of Medical herein Bayers leadership in agriculture provides tailored solutions NextPoint Therapeutics develops medications to expand the benefit of immunotherapies to cancer patients. | Learn more about Anne Koehler, PhD's . 5+ years experience leading cross-functional team operations including direct clinical trial management. It is committed to developing tumor cellular immunotherapeutics through its own innovative technology platforms. amended (the "U.S. Securities Act"), or any U.S. State security laws and may not be offered or sold 25. While immune checkpoint inhibitors targeting PD-1/L1 have revolutionized cancer treatments,. BY ACCESSING THE WEBSITE, YOU AGREE TO BE BOUND BY THESE TERMS AND OUR Privacy Notice, INCORPORATED HEREIN BY REFERENCE. Get the latest business insights from Dun & Bradstreet. Among these areas are oncology, immunology, rare diseases, vaccines, potential cures in other core areas of Sanofis business footprint, and digital health solutions. Bayer Global Future Leadership Program - Engineers, Potential, Leading for a hungry planet, Bayer for Prescription Medicine in Europe, Counterfeits in Agriculture, Recognize & MPM invests across the biotech landscape with its BioVentures venture capital offerings, and with impact and public equities products through its affiliate BioImpact Capital. Drive the clinical biomarker function to identify indications, support patient stratification and to inform on mechanism of action; develop, qualify, and execute biomarker assays with the most appropriate technical platforms to advance and support immune-oncology therapeutics to the clinic. NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi. In most cases, we need to process certain components of your Personal Data in order to fulfill our contractual obligations to you and for our legitimate interests. 2013 Jun 11;110(24):9879-84. By clicking on the I AGREE button, I confirm that I am permitted 5. Subject to applicable law, the purposes for which we use and process Personal Data, and the legal basis for such processing, are set forth below. Bayer Global Due to legal reasons, the following content is only available for specialized journalists. The support of our new investors along with the continued commitment of our existing investors and founders emphasizes our momentum and progress in defining precision immuno-oncology for new patient segments., Juergen Eckhardt, MD, Head of Leaps by Bayer, commented, Leaps by Bayer was founded to help solve ten of the worlds biggest challenges in health and agriculture, including preventing and curing cancer. to any legal entity which is a qualified investor as defined in the Prospectus Directive, to fewer than 150 natural or legal persons (other than qualified investors as defined in the - NextPoint Therapeutics, a Cambridge, Mass.-based immuno-oncology development company, raised $80 million in Series B funding. Please note that if you choose to erase or block your cookies, certain parts of our Site may not function correctly. Cookies can remember login information, preferences, and similar information. be made at any time under the following exemptions from the Prospectus Directive, if they have been Career Worldwide, Data Natural Scientists, Global The company offers to build a broad strategic pipeline of first-in-class immunotherapies based on a novel, validated checkpoint axis, expanding the potential of immunotherapy. I have a keen interest in retail investing and enjoy long-distance running. Global, Bayer Among these areas are oncology, immunology, rare diseases, vaccines, potential cures in other core areas of Sanofis business footprint, and digital health solutions. The company and its founders have shown in preclinical models and with analysis of existing clinical datasets that the HHLA2 pathway is an important tumor-suppressive mechanism in many patients3,4. The tender offer referenced herein is not being made, directly or indirectly, in or into the United Pharmacists, & Cambridge, MA February 21, 2023 NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today the appointment of Leena Gandhi, MD, PhD, as Chief Medical Officer (CMO). Drs. offering or an invitation to the public in connection with any offer within the meaning of NextPoint Therapeutics has announced an $80 million Series B funding round to move two lead precision immuno-oncology programs into the clinic. Founded by MPM Capital, NextPoint Therapeutics has assembled a team of proven drug developers to build a broad strategic pipeline of first-in-class immunotherapies based on this validated checkpoint axis, with the goal of delivering new options to people with cancer." Description Source: VentureRadar Research / Company Website PhD or MD in cancer biology, immunology, genomics, biochemistry, or molecular/cellular biologybackground in immunology and immuno-oncology biomarker development strongly preferred. Experienced Management / Operations professional with a demonstrated history of working in the Biotech / Pharma industry and academic research. The final prospectus, when published, will be we requirements under the U.S. Securities Act or to, or for the benefit of, U.S. persons. the world. Freemans and Zangs independent discovery and characterization of the HHLA2 pathway formed the basis of the NextPoint approach. Deforestation and Forest Degradation, Postion A spokesperson for Boston-based NextPoint declined . Zhao R, Chinai JM, Buhl S, et al. It was the company's first announced funding. 10+ years of pharmaceutical or biotechnology industry experience or mix of industry and academic experience in oncology or cancer immunotherapy with an emphasis on translational research, clinical biomarkers, and monoclonal antibodies, Proven track record of transitioning biomarkers from the bench to the clinic, Strong knowledge of immuno-oncology and associated biomarker approaches, Technical expertise in IHC, RNAscope, flow cytometry, genetics (including ctDNA), RNA-Seq, NanoString, qPCR and ELISAs, Proven success with filing INDs and supporting clinical trials, Competency with bioinformatic datasets and experience collaborating with bioinformaticians to analyze publicly available datasets, Excellent communication and interpersonal skills, personal integrity, professional manner, and ability to gain respect and develop good working relationships with cross functional personnel at all levels, Ability to balance multiple stakeholders and projects simultaneously, and able to operate with high accountability and under tight deadlines, Forward looking thinker, who actively seeks opportunities and proposes solutions with strong decision-making capability, A collaborator who communicates in an open, clear, complete, timely and consistent manner who listens effectively and invites response and discussion, Direct and run clinical operations and clinical trial launch activities for clinical programs, Manage clinical research organizations, clinical and testing lab vendors, Establish clinical operations infrastructure across the organization, Maintain relationships with Sites and KOLs, Represent NextPoint at Scientific and Investigator Meetings, Stay apprised of current trends in clinical trials research and regulatory landscape, Take responsibility for launch and day-to-day operational management of clinical trials including study sites, Participate in Clinical Vendor Governance and Safety Review Committee Meetings, Design and perform ligand binding assays in multi-well formats to analyze novel antibody therapeutics, Develop and execute functional assays involving primary human immune cells, mammalian cell culture, and multi-color flow cytometry to screen novel antibody therapeutics in an immune-oncology setting, Work independently to design and conduct experiments, analyze, interpret, and communicate data in team meetings and to leadership, Support the laboratory organization and operations by maintaining lab equipment and managing reagent and supply inventories, Bachelors degree in cell/molecular biology, immunology, or cancer biology or equivalent field, 2 + years hands-on experience in drug discovery research preferably in an industry setting, Experience with cell-based functional immune assays such as MLR, immune cell activity assays, and cytokine release assays, Experience with multiparameter flow cytometry, Hands on experience with murine tumor models preferred, Excellent verbal and written communication skills with a demonstrated ability to work collaboratively and thrive in a team environment, Excellent interpersonal skills and willingness to learn a variety of new techniques and technologies; flexibility to adapt to rapidly changing priorities and deadlines. http://tools.google.com/dlpage/gaoptout?hl=us, http://www.google.com/analytics/terms/us.html, https://optout.networkadvertising.org/?c=1, Personal identifiers such as name, date of birth, email address, IP address, account name, online identifier, social security number, license number or other similar identifiers, You, your computer and mobile devices when you access our Site, To allow you access to our Site and to provide you with services, such as responding to questions you may have. The Bayer brand stands for trust, reliability and quality throughout the world. Stockholders' Meeting, Notice archive, Shareholder Secret of the Bridge, Rice You can use our locations menu to You are currently on the Bayer global website. offer of the securities in any jurisdiction. permitted to view these materials, please exit this webpage. Global Product Strategy, Position 13353 Berlin Seek to obtain access to any materials or information through hacking, data harvesting or through other means we have not intentionally made available to you through the Website. To protect your privacy and security, we may take steps to verify your identity in order to respond to your request. offer within the meaning of Regulation (EU) 2017/1129. Menu, Our About NextPoint Therapeutics NextPoint is advancing the field of immuno-oncology through its leading scientific work on the novel HHLA2 pathway. on (DE), Bayer solutions Cambridge, MA / Leverkusen, Germany, January 10, 2023 NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-led by Leaps by Bayer, the impact investment arm of Bayer AG, and Sanofi Ventures, the strategic venture capital arm for Sanofi.